Already billed as a potential blockbuster, Amgen and AstraZeneca’s Tezspire has turned in strong clinical data in chronic ...

As Bristol Myers Squibb rolls ahead with its plan to cut $1.5 billion in costs by the end of the year, the drugmaker is once ...

Takeda made it rain zebras at a Boston Celtics game Friday. The stunt saw 100 toy zebras parachute from the arena’s rafters ...

| Dr. Buzón discusses bridging science and reality, highlighting the vital role of real-world evidence in advancing HIV care ...

Once again, Eli Lilly is using Hollywood’s biggest night as a platform to speak out on a hot-button issue in pharma. | Once ...

Merck is bracing for the years of sales growth from oncology superstar Keytruda to take a sharp turn in 2028—and for more ...

Amid Eisai’s efforts to capitalize on a potential growth surge for its Alzheimer’s disease med Leqembi, the Japanese ...

Get ready to see more of Henry Winkler on TV talking about geographic atrophy (GA). | During a quarterly conference call, as ...

Three months ago, in its third-quarter report, Madrigal pointed out that it achieved a key goal early by gaining 80% coverage ...

As Merck & Co. hunts for an ideal spot to set up a new commercial facility, Delaware is looking to bolster its odds with a ...

Eli Lilly is unleashing new ammunition in its fight against cheaper, compounded versions of its obesity blockbuster Zepbound.

Following a flurry of activity at this month’s meeting of the European Medicines Agency’s Committee for Medicinal Products ...